A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine [tick borne encephalitis vaccine] (free of protein-derived stabilizer) in study V48P4E1, five years after first booster immunization

Trial Profile

A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine [tick borne encephalitis vaccine] (free of protein-derived stabilizer) in study V48P4E1, five years after first booster immunization

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2007

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 06 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top